NCT04439578View on ClinicalTrials.gov

Effect of Rifampicin on the Pharmacokinetics of SHR6390 in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

June 23, 2020

Primary Completion Date

August 17, 2020

Study Completion Date

January 15, 2021

Conditions
Healthy Subjects
Interventions
DRUG

SHR6390 tablet single oral dose of SHR6390 or co-administered with rifampicin

600 mg rifampicin was administered in the morning.

Trial Locations (1)

310014

Zhejiang provincial people's hospital, Hangzhou

All Listed Sponsors
lead

Jiangsu HengRui Medicine Co., Ltd.

INDUSTRY

NCT04439578 - Effect of Rifampicin on the Pharmacokinetics of SHR6390 in Healthy Subjects | Biotech Hunter | Biotech Hunter